108552
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
鲁索替尼乳膏成功治疗儿童甲周扁平苔藓 1 例报告
Received 2 June 2025
Accepted for publication 2 September 2025
Published 14 September 2025 Volume 2025:18 Pages 2367—2370
DOI https://doi.org/10.2147/CCID.S542446
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Prof. Dr. Rungsima Wanitphakdeedecha
Anqi Sheng, Wenting Hu, Ai’e Xu
Department of Dermatology, Hangzhou Third People’s Hospital, Hangzhou, Zhejiang, People’s Republic of China
Correspondence: Ai’e Xu, Department of Dermatology, Hangzhou Third People’s Hospital, Hangzhou, Zhejiang, People’s Republic of China, Tel +86 13906536223, Email xuaiehz@msn.com
Abstract: The role of oral JAK inhibitors in the treatment of nail lichen planus (NLP) has recently been reported, but there have been no literature reports on the treatment of NLP with topical Janus kinase (JAK) inhibitor. We present, for the first time, a preliminary clinical experience with topical ruxolitinib cream, a JAK inhibitor, in a child with NLP. The remarkable results suggest topical ruxolitinib cream may be a potential treatment option for NLP.
Keywords: nail lichen planus, child, Janus kinase inhibitor, ruxolitinib cream
Department of Dermatology, Hangzhou Third People’s Hospital, Hangzhou, Zhejiang, People’s Republic of China
Correspondence: Ai’e Xu, Department of Dermatology, Hangzhou Third People’s Hospital, Hangzhou, Zhejiang, People’s Republic of China, Tel +86 13906536223, Email xuaiehz@msn.com
Abstract: The role of oral JAK inhibitors in the treatment of nail lichen planus (NLP) has recently been reported, but there have been no literature reports on the treatment of NLP with topical Janus kinase (JAK) inhibitor. We present, for the first time, a preliminary clinical experience with topical ruxolitinib cream, a JAK inhibitor, in a child with NLP. The remarkable results suggest topical ruxolitinib cream may be a potential treatment option for NLP.
Keywords: nail lichen planus, child, Janus kinase inhibitor, ruxolitinib cream